Ori C 902
Alternative Names: Ori-C902Latest Information Update: 31 Mar 2025
At a glance
- Originator OriCell Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Liver cancer
- Preclinical Solid tumours
Most Recent Events
- 24 Feb 2025 Phase-I clinical trials in Liver cancer (Late-stage disease, Second-line therapy or greater) in China (Parenteral) (NCT06891742)
- 21 Feb 2025 Ori C902 is available for licensing as of 18 Feb 2025. https://www.oricell.com/en/product/
- 18 Feb 2025 Preclinical trials in Liver cancer in China (Parenteral) prior to February 2025 (Oricell Therapeutics pipeline, February 2025)